<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Sept. 4, 2019 (HealthDay News) — For patients with type 2 diabetes and obesity, metabolic surgery is associated with a reduced risk for mortality and major adverse cardiovascular events, according to a study published online Sept. 2 in the Journal of the American Medical Association<\/i> to coincide with the European Society of Cardiology Congress 2019, held from Aug. 31 to Sept. 4 in Paris.<\/p>\n
Ali Aminian, M.D., from the Cleveland Clinic, and colleagues conducted a retrospective cohort study involving 2,287 adults with diabetes and obesity who underwent metabolic surgery. These patients were matched with 11,435 nonsurgical control patients with diabetes and obesity.<\/p>\n
The researchers found that at the end of the study period, 385 patients in the surgical group and 3,243 in the nonsurgical group experienced a primary end point (first occurrence of the composite of all-cause mortality, coronary artery events, cerebrovascular events, heart failure, nephropathy, and atrial fibrillation; cumulative incidence at eight years, 30.8 versus 47.7 percent; adjusted hazard ratio, 0.61). Statistically significant differences were seen in favor of metabolic surgery in all seven prespecified secondary outcomes including mortality. All-cause mortality occurred in 112 and 1,111 patients in the metabolic surgery and nonsurgery groups, respectively (cumulative incidence at eight years, 10.0 and 17.8 percent, respectively; adjusted hazard ratio, 0.59).<\/p>\n
“A well-designed randomized controlled trial is needed to definitively determine whether metabolic surgery can reduce the incidence of major heart problems in patients with type 2 diabetes and obesity,” a coauthor said in a statement.<\/p>\n
Abstract\/Full Text<\/a><\/p>\n Editorial<\/a><\/p>\n